Related references
Note: Only part of the references are listed.Multiyear Follow-up of AAV5-hFVIII-SQ Gene Therapy for Hemophilia A
K. John Pasi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Regional variation and cost implications of prescribed extended half-life factor concentrates among US Haemophilia Treatment Centres for patients with moderate and severe haemophilia
Stacy E. Croteau et al.
HAEMOPHILIA (2019)
New therapies using nonfactor products for patients with hemophilia and inhibitors
Keiji Nogami et al.
BLOOD (2019)
Emicizumab: Review of the literature and critical appraisal
E. Carlos Rodriguez-Merchan et al.
HAEMOPHILIA (2019)
Decision aids that facilitate elements of shared decision making in chronic illnesses: a systematic review
Thomas H. Wieringa et al.
SYSTEMATIC REVIEWS (2019)
Adeno-Associated Mediated Gene Transfer for Hemophilia B:8 Year Follow up and Impact of Removing Empty Viral Particles on Safety and Efficacy of Gene Transfer
Amit C. Nathwani et al.
BLOOD (2018)
The role of patient and healthcare professionals in the era of new hemophilia treatments in developed and developing countries
Fadi Nossair et al.
THERAPEUTIC ADVANCES IN HEMATOLOGY (2018)
Hemophilia B Gene Therapy with a High-Specific-Activity Factor IX Variant
L. A. George et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
AAV5-Factor VIII Gene Transfer in Severe Hemophilia A
Savita Rangarajan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
The cost of severe haemophilia in Europe: the CHESS study
Jamie O'Hara et al.
ORPHANET JOURNAL OF RARE DISEASES (2017)
Advances in the treatment of bleeding disorders
F. Peyvandi et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2016)
An innovative outcome-based care and procurement model of hemophilia management
Alessandro Gringeri et al.
EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH (2016)
Personalized Strategies to Activate and Empower Patients in Health Care and Reduce Health Disparities
Jie Chen et al.
HEALTH EDUCATION & BEHAVIOR (2016)
AAV liver expression of FIX-Padua prevents and eradicates FIX inhibitor without increasing thrombogenicity in hemophilia B dogs and mice
Julie M. Crudele et al.
BLOOD (2015)
Burden of illness: direct and indirect costs among persons with hemophilia A in the United States
Zheng-Yi Zhou et al.
JOURNAL OF MEDICAL ECONOMICS (2015)
Treatment decision-making among Canadian youth with severe haemophilia: a qualitative approach
S. J. Lane et al.
HAEMOPHILIA (2015)
Joining the patient on the path to customized prophylaxis: one hemophilia team explores the tools of engagement
Deborah Gue et al.
JOURNAL OF MULTIDISCIPLINARY HEALTHCARE (2015)
Developing a two-sided intervention to facilitate shared decision-making in haemophilia: decision boxes for clinicians and patient decision aids for patients
A. Athale et al.
HAEMOPHILIA (2014)
Long-Term Safety and Efficacy of Factor IX Gene Therapy in Hemophilia B
A. C. Nathwani et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Therapeutic levels of FVIII following a single peripheral vein administration of rAAV vector encoding a novel human factor VIII variant
Jenny McIntosh et al.
BLOOD (2013)
A qualitative study identifying the knowledge, attitudes and behaviours of young men with mild haemophilia
J. Nilson et al.
HAEMOPHILIA (2012)
Adenovirus-Associated Virus Vector-Mediated Gene Transfer in Hemophilia B
Amit C. Nathwani et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Eradication of neutralizing antibodies to factor VIII in canine hemophilia A after liver gene therapy
Jonathan D. Finn et al.
BLOOD (2010)
EMERGENCY DEPARTMENT CARE FOR PATIENTS WITH HEMOPHILIA AND VON WILLEBRAND DISEASE
Tammuella Singleton et al.
JOURNAL OF EMERGENCY MEDICINE (2010)
Consolidated criteria for reporting qualitative research (COREQ): a 32-item checklist for interviews and focus groups
Allison Tong et al.
INTERNATIONAL JOURNAL FOR QUALITY IN HEALTH CARE (2007)
Share Paper
